Clinical Trial Update: Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib [Phase 2]

View source ↗

Summary

A Phase II study of Rituximab, Lenalidomide, and Ibrutinib in Diffuse Large B-Cell Lymphoma Unclassifiable has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma Unclassifiable

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable | Phase 2 | Status: COMPLETED | Results posted: 2024-03-13